Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21)
Interactions between circulating tumour cells (CTCs) and platelets are thought to inhibit natural killer(NK)-cell-induced lysis. We attempted to correlate CTC numbers in men with advanced prostate cancer with platelet counts and circulating lymphocyte numbers. Sixty-one ExPeCT trial participants, di...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/18/4690 |
id |
doaj-495572ca71384de3b85662b15fb4d082 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Brian Hayes Lauren Brady Gráinne Sheill Anne-Marie Baird Emer Guinan Bryan Stanfill Jean Dunne Dean Holden Tatjana Vlajnic Orla Casey Verena Murphy John Greene Emma H. Allott Juliette Hussey Fidelma Cahill Mieke Van Hemelrijck Nicola Peat Lorelei A. Mucci Moya Cunningham Liam Grogan Thomas Lynch Rustom P. Manecksha John McCaffrey Dearbhaile M. O’Donnell Orla Sheils John J. O’Leary Sarah Rudman Ray McDermott Stephen Finn |
spellingShingle |
Brian Hayes Lauren Brady Gráinne Sheill Anne-Marie Baird Emer Guinan Bryan Stanfill Jean Dunne Dean Holden Tatjana Vlajnic Orla Casey Verena Murphy John Greene Emma H. Allott Juliette Hussey Fidelma Cahill Mieke Van Hemelrijck Nicola Peat Lorelei A. Mucci Moya Cunningham Liam Grogan Thomas Lynch Rustom P. Manecksha John McCaffrey Dearbhaile M. O’Donnell Orla Sheils John J. O’Leary Sarah Rudman Ray McDermott Stephen Finn Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21) Cancers prostate cancer circulating tumour cells exercise flow cytometry platelets inflammation |
author_facet |
Brian Hayes Lauren Brady Gráinne Sheill Anne-Marie Baird Emer Guinan Bryan Stanfill Jean Dunne Dean Holden Tatjana Vlajnic Orla Casey Verena Murphy John Greene Emma H. Allott Juliette Hussey Fidelma Cahill Mieke Van Hemelrijck Nicola Peat Lorelei A. Mucci Moya Cunningham Liam Grogan Thomas Lynch Rustom P. Manecksha John McCaffrey Dearbhaile M. O’Donnell Orla Sheils John J. O’Leary Sarah Rudman Ray McDermott Stephen Finn |
author_sort |
Brian Hayes |
title |
Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21) |
title_short |
Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21) |
title_full |
Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21) |
title_fullStr |
Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21) |
title_full_unstemmed |
Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21) |
title_sort |
circulating tumour cell numbers correlate with platelet count and circulating lymphocyte subsets in men with advanced prostate cancer: data from the expect clinical trial (ctrial-ie 15-21) |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-09-01 |
description |
Interactions between circulating tumour cells (CTCs) and platelets are thought to inhibit natural killer(NK)-cell-induced lysis. We attempted to correlate CTC numbers in men with advanced prostate cancer with platelet counts and circulating lymphocyte numbers. Sixty-one ExPeCT trial participants, divided into overweight/obese and normal weight groups on the basis of a BMI ≥ 25 or <25, were randomized to participate or not in a six-month exercise programme. Blood samples at randomization, and at three and six months, were subjected to ScreenCell filtration, circulating platelet counts were obtained, and flow cytometry was performed on a subset of samples (<i>n</i> = 29). CTC count positively correlated with absolute total lymphocyte count (r<sup>2</sup> = 0.1709, <i>p</i> = 0.0258) and NK-cell count (r<sup>2</sup> = 0.49, <i>p</i> < 0.0001). There was also a positive correlation between platelet count and CTC count (r<sup>2</sup> = 0.094, <i>p</i> = 0.0001). Correlation was also demonstrated within the overweight/obese group (<i>n</i> = 123, <i>p</i> < 0.0001), the non-exercise group (<i>n</i> = 79, <i>p</i> = 0.001) and blood draw samples lacking platelet cloaking (<i>n</i> = 128, <i>p</i> < 0.0001). By flow cytometry, blood samples from the exercise group (<i>n</i> = 15) had a higher proportion of CD3+ T-lymphocytes (<i>p</i> = 0.0003) and lower proportions of B-lymphocytes (<i>p</i> = 0.0264) and NK-cells (<i>p</i> = 0.015) than the non-exercise group (<i>n</i> = 14). These findings suggest that CTCs engage in complex interactions with the coagulation cascade and innate immune system during intravascular transit, and they present an attractive target for directed therapy at a vulnerable stage in metastasis. |
topic |
prostate cancer circulating tumour cells exercise flow cytometry platelets inflammation |
url |
https://www.mdpi.com/2072-6694/13/18/4690 |
work_keys_str_mv |
AT brianhayes circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT laurenbrady circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT grainnesheill circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT annemariebaird circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT emerguinan circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT bryanstanfill circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT jeandunne circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT deanholden circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT tatjanavlajnic circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT orlacasey circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT verenamurphy circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT johngreene circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT emmahallott circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT juliettehussey circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT fidelmacahill circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT miekevanhemelrijck circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT nicolapeat circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT loreleiamucci circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT moyacunningham circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT liamgrogan circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT thomaslynch circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT rustompmanecksha circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT johnmccaffrey circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT dearbhailemodonnell circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT orlasheils circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT johnjoleary circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT sarahrudman circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT raymcdermott circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 AT stephenfinn circulatingtumourcellnumberscorrelatewithplateletcountandcirculatinglymphocytesubsetsinmenwithadvancedprostatecancerdatafromtheexpectclinicaltrialctrialie1521 |
_version_ |
1717367741446356992 |
spelling |
doaj-495572ca71384de3b85662b15fb4d0822021-09-25T23:50:22ZengMDPI AGCancers2072-66942021-09-01134690469010.3390/cancers13184690Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21)Brian Hayes0Lauren Brady1Gráinne Sheill2Anne-Marie Baird3Emer Guinan4Bryan Stanfill5Jean Dunne6Dean Holden7Tatjana Vlajnic8Orla Casey9Verena Murphy10John Greene11Emma H. Allott12Juliette Hussey13Fidelma Cahill14Mieke Van Hemelrijck15Nicola Peat16Lorelei A. Mucci17Moya Cunningham18Liam Grogan19Thomas Lynch20Rustom P. Manecksha21John McCaffrey22Dearbhaile M. O’Donnell23Orla Sheils24John J. O’Leary25Sarah Rudman26Ray McDermott27Stephen Finn28Department of Histopathology, Cork University Hospital, T12DC4A Cork, IrelandDepartment of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, D08NHY1 Dublin, IrelandDiscipline of Physiotherapy, School of Medicine, Trinity College Dublin, D08NHY1 Dublin, IrelandDepartment of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, D08NHY1 Dublin, IrelandTrinity Centre for Health Sciences, School of Medicine, Trinity College Dublin, D08NHY1 Dublin, IrelandPacific Northwest National Laboratory, Richland, WA 99352, USADepartment of Immunology, St James’s Hospital, D08NHY1 Dublin, IrelandDepartment of Immunology, St James’s Hospital, D08NHY1 Dublin, IrelandInstitute of Pathology, University Hospital Basel, 4056 Basel, SwitzerlandCancer Trials Ireland, D11KXN4 Dublin, IrelandCancer Trials Ireland, D11KXN4 Dublin, IrelandDepartment of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, D08NHY1 Dublin, IrelandDepartment of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, D08NHY1 Dublin, IrelandDiscipline of Physiotherapy, School of Medicine, Trinity College Dublin, D08NHY1 Dublin, IrelandKing’s College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology (TOUR), London SE1 9RT, UKKing’s College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology (TOUR), London SE1 9RT, UKGuy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UKDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USADepartment of Radiation Oncology, St Luke’s Hospital, D06HH36 Dublin, IrelandDepartment of Oncology, Beaumont Hospital, D09V2N0 Dublin, IrelandDepartment of Urology, St James’s Hospital, D08NHY1 Dublin, IrelandDepartment of Urology, St James’s Hospital, D08NHY1 Dublin, IrelandDepartment of Oncology, Mater Misericordiae Hospital, D07AX57 Dublin, IrelandHOPE Directorate, St James’s Hospital, D08NHY1 Dublin, IrelandDepartment of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, D08NHY1 Dublin, IrelandDepartment of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, D08NHY1 Dublin, IrelandGuy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UKDepartment of Oncology, Tallaght University Hospital, D24NR0A Dublin, IrelandDepartment of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, D08NHY1 Dublin, IrelandInteractions between circulating tumour cells (CTCs) and platelets are thought to inhibit natural killer(NK)-cell-induced lysis. We attempted to correlate CTC numbers in men with advanced prostate cancer with platelet counts and circulating lymphocyte numbers. Sixty-one ExPeCT trial participants, divided into overweight/obese and normal weight groups on the basis of a BMI ≥ 25 or <25, were randomized to participate or not in a six-month exercise programme. Blood samples at randomization, and at three and six months, were subjected to ScreenCell filtration, circulating platelet counts were obtained, and flow cytometry was performed on a subset of samples (<i>n</i> = 29). CTC count positively correlated with absolute total lymphocyte count (r<sup>2</sup> = 0.1709, <i>p</i> = 0.0258) and NK-cell count (r<sup>2</sup> = 0.49, <i>p</i> < 0.0001). There was also a positive correlation between platelet count and CTC count (r<sup>2</sup> = 0.094, <i>p</i> = 0.0001). Correlation was also demonstrated within the overweight/obese group (<i>n</i> = 123, <i>p</i> < 0.0001), the non-exercise group (<i>n</i> = 79, <i>p</i> = 0.001) and blood draw samples lacking platelet cloaking (<i>n</i> = 128, <i>p</i> < 0.0001). By flow cytometry, blood samples from the exercise group (<i>n</i> = 15) had a higher proportion of CD3+ T-lymphocytes (<i>p</i> = 0.0003) and lower proportions of B-lymphocytes (<i>p</i> = 0.0264) and NK-cells (<i>p</i> = 0.015) than the non-exercise group (<i>n</i> = 14). These findings suggest that CTCs engage in complex interactions with the coagulation cascade and innate immune system during intravascular transit, and they present an attractive target for directed therapy at a vulnerable stage in metastasis.https://www.mdpi.com/2072-6694/13/18/4690prostate cancercirculating tumour cellsexerciseflow cytometryplateletsinflammation |